Global Collaborations Continue to Validate Dyadic's C1 Platform and Expands Commercial Potential

2026-07-07 07:25:00

Global Collaborations Continue to Validate Dyadic's C1 Platform and Expand Commercial Opportunity Dyadic's Ebola preparedness work highlights C1's potentia

Dyadic Expands IP Protection and Business Development Activities in Japan

2026-06-29 07:25:00

JUPITER, Fla., June 29, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI) (“Dyadic” or the “Company”), d/b/a Dyadic Applied BioSolutions, a biotechnology company focused on the development and commercialization of scalable microbial protein production platforms for use across life sciences, food, nutrition, industrial, and biopharmaceutical sectors, today announced that the Japan Patent Office has allowed claims covering its proprietary Thermothelomyces heterothallica recombinant protein expression technology.

An Interview with the President & COO: How Dyadic is Commercializing Its Protein Platform Across Multi-Billion-Dollar Markets

2026-06-22 08:46:00

SmallCaps Daily Sits Down with Joe Hazelton to Discuss Dyadic's Product Strategy, Strategic Partnerships, and Long-Term Growth Vision New York, New York--(Newsfile Corp. - June 22, 2026) - Dyadic Applied BioSolutions, Inc. (NASDAQ: DYAI) ("Dyadic" or the "Company") is entering the next phase of its growth strategy as it expands commercialization efforts across Life Sciences, Food & Nutrition, and Bio-industrial markets. SmallCaps Daily sat down with President and Chief Operating Officer Joe Hazelton to discuss the Company's product portfolio, strategic partnerships, and growing opportunities in non-animal proteins.

Dyadic Highlights Accelerated Interest in C1 Biomanufacturing Platform Amid Ebola Preparedness Activities and Growing Commercial Adoption

2026-06-15 07:25:00

JUPITER, Fla., June 15, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI), d/b/a Dyadic Applied BioSolutions (“Dyadic” or the “Company”), a biotechnology company focused on the development and commercialization of scalable microbial protein production platforms, today highlighted increasing interest in its proprietary C1 protein production platform as global infectious disease preparedness efforts intensify in response to the ongoing Bundibugyo Ebola virus (BDBV) outbreak and as the Company continues to advance commercial adoption across multiple high-growth markets.

Dyadic and Scripps Research Collaborate on Rapid-Response Hantavirus Antibody and Vaccine Development

2026-05-28 07:25:00

JUPITER, Fla., May 28, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic,” “we,” “us,” “our,” or the “Company”) (NASDAQ: DYAI), d/b/a Dyadic Applied BioSolutions, a biotechnology company focused on the development and commercialization of scalable microbial protein production platforms for use across life sciences, food, nutrition, industrial, and biopharmaceutical applications, today announced that Dyadic Applied BioSolutions and researchers at Scripps Research are collaborating to evaluate monoclonal antibody and vaccine candidates targeting hantaviruses, including Andes virus, a hantavirus strain associated with Hantavirus Pulmonary Syndrome (HPS), a severe and potentially fatal respiratory disease in humans.

Dyadic to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026

2026-05-21 16:05:00

JUPITER, Fla., May 21, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), d/b/a Dyadic Applied BioSolutions, a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for diverse commercial applications, will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2026 Investor Conference, taking place virtually on Thursday, May 28, 2026.

Skyline Corporate Communications Group, LLC Announces Dyadic Applied BioSolutions to Deliver a Live Presentation at the Skyline Signature Series™ on Wednesday, May 27 at 12:00 PM ET

2026-05-21 15:45:00

Company invites individual and institutional investors, as well as advisors and analysts, to attend this real-time, interactive presentation at the Skyline Signature Series™ Company invites individual and institutional investors, as well as advisors and analysts, to attend this real-time, interactive presentation at the Skyline Signature Series™

Dyadic Applied BioSolutions Announces Participation in Sidoti Virtual Investor Conference

2026-05-19 09:35:00

JUPITER, Fla. , May 19, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic," "we," "us," "our," or the "Company") (NASDAQ: DYAI), d/b/a Dyadic Applied BioSolutions, a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for diverse commercial applications, today announced that Joe Hazelton, Dyadic's President and Chief Operating Officer, will present at Sidoti's Virtual Investor Conference on May 20-21, 2026.